<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200819048461N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-21</date_registration>
      <primary_sponsor>Islamic Azad University</primary_sponsor>
      <public_title>The effect of exercise and curcumin on hemodialysis disease</public_title>
      <acronym></acronym>
      <scientific_title>The effect of cimbination of exercise and curcumin supplementation on serum ferritin and serum albumin in hemodialysis patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-03</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67130</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: En Simple randomization, individual with random number generation program
Randomization was performed by a biostatistician using a computer-generated randomization program [using Stata 16, StataCrop, College Station, Tx] with an allocation ratio of 1:1.
For allocation concealment, allocation information will be protected in opaque sealed envelopes by an identified individual not participating in the study. Only after participant registration and baseline measurements are completed will envelopes be opened, Blinding description: One of the experimental groups of the research was the exercise + supplement group, which received the supplement in the form of capsules along with doing sports exercises, and the second experimental group was the exercise group, which only exercised and a capsule that looked similar to the supplement capsule but contained He was receiving curcumin.</study_design>
      <phase>N/A</phase>
      <hc_freetext>End stage renal disease.</hc_freetext>
      <i_freetext>Intervention 1: The first intervention group :the experimental group will do 3 sessions of 45-minute exercise program per week at home on non-dialysis days with the simultaneous supervision of an online trainer for 12 weeks. These exercises are taught face-to-face in the first week. resistance exercises (2 sets of 12 repetitions, including anterior and posterior knee strengthening, lateral hip joint strengthening (adductors and abductors), strengthening of the anterior and posterior leg system, rest period between sets 30 to 60 secondsconsidered) aerobic exercise (3 turns of 15 repetitions of walking backwards, walking and turning, walking sideways, stopping on heels and toes, walking on heels and toes and walking on stairs). It is worth mentioning that before and after each training session, the subjects performed static stretching and softening movements to warm up and cool down the body. Intervention 2: The second intervention group :The experimental group will receive curcumin supplements in the form of capsules for 12 weeks, in such a way that these capsules will be delivered to them once every 3 weeks. All capsules will be the same in terms of shape, quantity, size, and color.Theparticipants will be asked to take 2 capsules of curcumin daily (equivalent to 1000 mg of curcumin) preferably after the main meal. Intervention 3: The third intervention group : the exercise group was +supplement. The subjects in this group, along with the exercise group, performed combined exercises, and during the research period, they received 1000 mg of curcumin supplement (manufactured by Dineh company) daily for 12 weeks. Intervention 4: Control group: Subjects in this group did not do any exercise during the research period (12 weeks) and did not receive any supplements.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The results of the study group are made available

When:
After october 2023

To whom:
Only academics are allowed

Conditions:
If the data is used for the purpose of research in the field of variables and providing new solutions, it can be used by mentioning the source

Where to obtain:
by email m.tabibi@ut.ac.ir

How to obtain:
It will be answered within one month after receiving the email

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mehsa Soleimani Sadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Gulzar 5</address>
        <city>Fouladshahr-Maskan Mehr</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8491153979</zip>
        <telephone>+98 31 5243 5855</telephone>
        <email>soleymanymahsa1375@gmail.com</email>
        <affiliation>Islamic Azad University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Doctor Mohammad Ali Tabibi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>71 alley.Jey street</address>
        <city>Esfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8174757536</zip>
        <telephone>031335252020</telephone>
        <email>m.tabibi@ut.ac.ir</email>
        <affiliation>Pardis  Specialist Wellness Institute</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 18 and 80 years
More than three months of dialysis experience
Having a three-time hemodialysis program
No heart attack and stroke in the past three months
Having the ability to communicate with others
The permission of the attending physician to practice
be clinically stable</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Unstable heart condition (angina, congestive heart failure, severe arterial stenosis, uncontrolled arrhythmias, etc.)
Active infection or acute medical illness
Hemodynamic instability, unstable blood sugar
unable to exercise (lower limb amputation without prosthesis)
Having severe skeletal-muscular pain at rest or minimal activity
Having shortness of breath while resting or with daily activities
Allergy or insensitivity to turmeric</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N18.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Chronic kidney disease, stage 5</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first intervention group :the experimental group will do 3 sessions of 45-minute exercise program per week at home on non-dialysis days with the simultaneous supervision of an online trainer for 12 weeks. These exercises are taught face-to-face in the first week. resistance exercises (2 sets of 12 repetitions, including anterior and posterior knee strengthening, lateral hip joint strengthening (adductors and abductors), strengthening of the anterior and posterior leg system, rest period between sets 30 to 60 secondsconsidered) aerobic exercise (3 turns of 15 repetitions of walking backwards, walking and turning, walking sideways, stopping on heels and toes, walking on heels and toes and walking on stairs). It is worth mentioning that before and after each training session, the subjects performed static stretching and softening movements to warm up and cool down the body.</i_keyword>
      <i_keyword>The second intervention group :The experimental group will receive curcumin supplements in the form of capsules for 12 weeks, in such a way that these capsules will be delivered to them once every 3 weeks. All capsules will be the same in terms of shape, quantity, size, and color.Theparticipants will be asked to take 2 capsules of curcumin daily (equivalent to 1000 mg of curcumin) preferably after the main meal.</i_keyword>
      <i_keyword>The third intervention group : the exercise group was +supplement. The subjects in this group, along with the exercise group, performed combined exercises, and during the research period, they received 1000 mg of curcumin supplement (manufactured by Dineh company) daily for 12 weeks.</i_keyword>
      <i_keyword>Control group: Subjects in this group did not do any exercise during the research period (12 weeks) and did not receive any supplements</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The normal level of ferritin in serum is between 10 and 300 nanograms per milliliter, and ferritin levels above 200 nanograms per milliliter in women and above 300 nanograms per milliliter in men have been diagnosed as abnormal. Serum ferritin levels in hemodialysis patients measurement of serum ferritin in the bloodstream can be useful for monitoring the progress of hemodialysis disease. Timepoint: Ferritin measurement of the subjects' blood was done in two stages, the first stage in the initial blood sampling, i.e. 24 hours before the start of the exercise protocol and curcumin supplementation, and the second stage in the blood sample of the last stage, three months after the last exercise session and the last curcumin intake a done. Method of measurement: To measure serum ferritin, it was measured and recorded using the ARKA kit by ELISA method (Enzyme-linked immunoadsorbent assay).</prim_outcome>
      <prim_outcome>Serum albumin level, the normal level of serum albumin is between 4.3 and 4.5 grams per deciliter, and hemodialysis patients have low albumin levels. Measuring the amount of serum albumin in the bloodstream can be useful for monitoring the progress of hemodialysis patients. Timepoint: Measuring the blood albumin of the subjects in two stages, the first stage in the initial blood sampling, i.e. 24 hours before the start of the exercise protocol and taking curcumin supplement and the second stage, in the final stage blood sampling, three months after the last session of sports training and the last curcumin intake a done . Method of measurement: The amount of albumin was measured and recorded by the Bionik laboratory kit, using the autoanalyzer olympus model AU made in Iran.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Functional status. Timepoint: Before starting exercise and taking curcumin and three months later. Method of measurement: 6-minute walking test.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Islamic Azad University of Khorasgan, Isfahan</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-09-05</approval_date>
        <contact_name>Research ethics committee</contact_name>
        <contact_address>J Sharghi St., Arghavanieh Esfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
